FDA Advisory Committees on the Brink: More Meetings, Fewer Members

A year ago, Congress sent FDA two very clear, somewhat contradictory messages: Hold more advisory committee meetings, but without the use of many expert panelists used in the past. The result is a system that is stretched to the limits.

These days, everyone is being asked to do more with less.

The Food & Drug Administration is no exception. Congress is asking FDA hold more advisory committee reviews for new product applications, while at the same time forcing the agency to...

More from Archive

More from Pink Sheet